Sign in

    Vineet Agra

    Research Analyst at Citigroup Inc.

    Vineet Agra is an Analyst at Citigroup Inc., specializing in equity research with a focus on the biotechnology and pharmaceutical sectors. He has covered companies such as Alvotech SA, contributing to investment analysis and earnings call inquiries to deepen sector insights. Agra began his role at Citigroup in recent years; available records primarily associate his tenure and coverage with Alvotech, and further details about his previous experience or full career history are limited. Professional credential data, such as FINRA registration or securities licenses, is currently undisclosed.

    Vineet Agra's questions to Alvotech (ALVO) leadership

    Vineet Agra's questions to Alvotech (ALVO) leadership • Q1 2024

    Question

    An analyst from Citi, likely Vineet Agra, asked about the significance of the interchangeability designation for gaining market share, especially since a competitor appears unconcerned about not having it and the FDA is reportedly pushing for more general labeling.

    Answer

    Chief Commercial Officer Anil Okay responded that Alvotech views interchangeability as a 'significant advantage.' He emphasized that the benefit extends beyond the designation itself to the market exclusivity it provides, which for Alvotech's HUMIRA biosimilar lasts until at least May 2025. He added that interchangeability is very helpful in reducing the 'friction of conversion' for patients.

    Ask Fintool Equity Research AI